Currently, a U.S. launch for Cialis is projected to take
place in 2003.

"Based on its clinical profile, we are confident in the value
and potential of Cialis," said Paul Clark, ICOS chairman and chief
executive officer. "This action by the FDA brings Cialis one step
closer to approval in the U.S., and we are confident Lilly ICOS can
fulfill the FDA's additional requests in a timely manner."

"We are committed to making Cialis an available treatment option
for the more than 30 million American men who are affected by
erectile dysfunction," said Sidney Taurel, chairman, president, and
chief executive officer of Eli Lilly and Company. "Lilly ICOS will
continue working with the FDA to bring this innovative compound to
market as expeditiously as possible."

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.